评估与骨质疏松症相关的抗药物不良事件的风险:基于FAERS数据库的药监测研究
Nan Yang1, Xiang Han1, Hongning Hua1
1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Frontiers in pharmacology
|October 29, 2025
概括
这项研究发现了新的证据,将四种抗药物 - - 氨酸,氨酸, gabapentin 和 eslicarbazepine - - 与骨质疏松症联系起来. 这些发现对于在使用这些药物的患者中预防骨密度下降至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 骨的新陈代谢 骨的新陈代谢
- 药品安全 药品安全
背景情况:
- 与抗药物 (AED) 相关的骨质疏松风险仍在争论中.
- 需要现实世界的数据来澄清这些关联.
- 现有的研究还没有全面评估所有常用的AED.
研究的目的:
- 使用现实世界的数据调查AED和骨质疏松症之间的关联.
- 为了确定与骨质疏松症相关的特定AED.
- 为临床指导和预防策略提供证据.
主要方法:
- 利用美国食品和药物管理局不良事件报告系统 (FAERS) (2005-2025) 的数据.
- 使用不成比例分析和邦费罗尼校正来检测安全信号.
- 根据年龄和性别进行了子组分析.
主要成果:
- 在与12种AED相关的206,680个不良事件中,确定了181个骨质疏松症事件.
- 检测到芬伊托因,酸, gabapentin 和 eslicarbazepine 的显著药物安全信号.
- 亚组分析探讨了风险的人口差异.
结论:
- 这项研究提供了第一个系统的证据,将氨酸,氨酸, gabapentin 和 eslicarbazepine 与骨质疏松症联系起来.
- 这些发现挑战了关于酸的现有知识差距,并引发了对 gabapentin 和 eslicarbazepine 的新担忧.
- 结果为临床医生提供了重要的见解,以识别和预防AED相关的骨质疏松症.
相关概念视频
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:20Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
01:14Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K